The next is excerpted from an internet article posted by MedicalXpress.
A cross-sectional evaluation from Yale College of Drugs estimates that roughly 5.8 million adolescents and 11.1 million younger adults in the USA meet eligibility standards for glucagon-like peptide-1 receptor agonists (GLP-1RAs), medication authorized to deal with weight problems and kind 2 diabetes (T2D) in some pediatric populations.
Prevalence of weight problems and T2D has continued to rise amongst U.S. youth, presenting a chance to deal with with GLP-1RAs. Earlier research have examined prescribing traits, although scientific and insurance coverage profiles of these eligible for GLP-1RAs stay poorly described.
Within the research, “Glucagon-Like Peptide-1 Receptor Agonist Eligibility Amongst US Adolescents and Younger Adults,” revealed in JAMA Pediatrics, researchers pooled knowledge from the Nationwide Well being and Diet Examination Survey (NHANES) to determine U.S. youth assembly FDA standards for GLP-1RA remedy.
Pattern knowledge included 572 adolescents aged 12–17 and 590 younger adults aged 18–25, representing a weighted estimate of 5.8 million adolescents and 11.1 million younger adults.
Eligibility standards for adolescents included T2D or weight problems primarily based on physique mass index (BMI) thresholds adjusted for age and intercourse or corresponding grownup BMI thresholds. For younger adults, eligibility included T2D, weight problems, or a weight-related situation akin to dyslipidemia, hypertension, heart problems, or T2D.
Supply: MedicalXpress
https://medicalxpress.com/information/2025-08-million-youth-criteria-glp-1ra.html
